【摘要】 许多研究表明人参皂苷是人参中起主要药效活性的物质,尤其是人参稀有皂苷比人参主皂苷在抗癌、抗心脑血管病、抗糖尿病等方面具有更好的疗效。利用从17年生野山参中分离、筛选获得一株人参内生真菌Burkholderia sp. GE 17-7生物转化人参主皂苷。通过薄层色谱法、高效液相色谱法等方法对人参主皂苷(Rb1、Rb2、Rc、Rd、Re和Rg1)的转化产物进行分离纯化,采用波谱解析及理化常数对其进行结构鉴定。同时,对转化路径进行了分析。结果表明人参内生真菌Burkholderia sp. GE 17-7能够特异性水解原人参二醇型皂苷C-20位糖基,对其内部糖基不具有水解特性。经鉴定其转化产物为人参稀有皂苷Rg3。转化路径为人参皂苷Rb1→人参皂苷Rd→人参稀有皂苷Rg3。人参内生真菌Burkholderia sp. GE 17-7能够特异性制备人参稀有皂苷Rg3,为工业制备人参稀有皂苷提供了新的微生物资源。更多还原

【Abstract】 Many investigational studies have shown that ginsenosides are the principal active constituents of ginseng in antioxidant, antineoplastic, anti-inflammatory and biomodulatory processes. In particular, minor ginsenoside monomers, such as F2, Rh2, Rg3 and compound K(CK), have greater antitumor activity than the major ginsenoside monomers Rb1, Rb2, Rc, Rd, Re and Rg1. An endophytic bacterium GE 17-7 strain isolated from ginseng roots for 17 years, belonging to the genus Burkholderia, had been used in converting minor ginsenosides. The major ginsenoside monomers Rb1, Rb2, Rc, Rd, Re and Rg1 were used by strain GE 17-7. Biotransformation products were separated and purified through thin-layer chromatography(TLC) and high performance liquid chromatography(HPLC) analysis and identified by spectral analysis and physical constants. The results indicated that Burkholderia sp. GE 17-7 had specific hydrolytic activity for the outer glucose at the C-20 position in protopanaxadiol-type ginsenosides without hydrolysis of the inner glucose. The final metabolite was ginsenoside Rg3 by nuclear magnetic resonance(NMR) analysis. This suggests that the hydrolytic pathway of ginsenoside Rb1 by strain GE 17-7 was ginsenoside Rb1→ginsenoside Rd→ginsenoside Rg3. We have successfully found a specificity ginsenoside Rg3-producing endophytic bacterium GE 17-7 from ginseng.更多还原